Products for Research Use Only
RegisterLogin

Dovramilast

CAT: 0804-HY-147263-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-147263-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid -mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB).
CAS Number
340019-69-4
Product Name Alternative
CC-11050
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/dovramilast.html
Purity
99.66
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1CC1)NC2=CC=CC(CN3[C@@H](C4=CC=C(OC)C(OCC)=C4)CS(=O)(C)=O)=C2C3=O
Molecular Formula
C24H28N2O6S
Molecular Weight
472.55
Precautions
H302, H315, H319
References & Citations
[1]International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information, Vol. 36, No. 2, 2022.|[2]Selvakumar Subbian, et al. Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis. Front Immunol. 2016 Jun 17;7:238.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PDE4

Alternative Products

CatalogName
BA8184-1Dovramilast
CS-O-58616Dovramilast-d3
CS-O-58615Dovramilast-13CD3

Popular Products